FDA DEVICE FACTS
HydroPICC 4Fr Single Lumen Marked catheter, 130 cm guidewire - Basic Kit (70001301); HydroPICC 4Fr Single Lumen Marked catheter, 70 cm guidewire - Basic Kit (70001302); HydroPICC 4Fr Single Lumen Marked catheter - Maximal Barrier kit (70001304); HydroPICC 5Fr Dual Lumen Marked catheter, 130 cm guidewire - Basic Kit (70002301); HydroPICC 5Fr Dual Lumen Marked catheter, 70 cm guidewire - Basic Kit (70002302); HydroPICC 5Fr Dual Lumen Marked catheter - Maximal Barrier kit (70002304); Hydr
Access Vascular, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
HydroP ICC Single Lumen: Indicated for short-or long-term peripheral access to the central venous system for intravenous therapy , including but not limited to the administration of fluids, medications, and nutrients; the sampling of blood; central venous pressure monitoring; and power injection of contrast media. Rated for maximum power injection flow rate of 5.0 ml/s HydroPICC Dual Lumen: Indicated for short- or long-term peripheral access to the central venous system for intravenous therapy , including but not limited to the administration of fluids, medications, and nutrients; the sampling of blood; central venous pressure monitoring; and power injection of contrast media . Rated for a maximum power injection flow rate of 5.0 ml/s HydroMID Single Lumen: Indicated for short term access( < 30 days) to the peripheral venous access system for intravenous therapy, including but not limited to, the administration of fluids , medications, and the sampling of blood and blood products. Maximum Power Injection Flow Rate: 4Fr Single Lumen, 20cm: 6 ml/sec The Hydro Catheter lines incorporate MIMIX® Technol ogy, an anti-thrombogenic bulk hydrogel material , designed to minimize the risk of thrombus formation on device surfaces . In vitro studies have demonstrated that both the external surfaces and internal fluid pathways of the catheter effectively reduce thrombus accumulation and thrombotic occlusions . This reduction in thrombus accumulation is achieved due to the catheter 's steric barrier. The clinical impact has not been evaluated in human clinical trials. This device is not intended for the treatment of existing vein thrombosis.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。